Is sarcopenia effective on survival in patients with metastatic gastric cancer?

Table 2 Univariate and multivariate analysis of clinicopathologic characteristics on survival

Clinicopathologic characteristics	Univariate analyses, HR (95%CI)	P value	Multivariate analyses, HR (95%CI)	P value
Age in yr, < 65 vs ≥ 65	1.366 (0.942-1.979)	0.100	N/A	N/A
Sex, female vs male	0.963 (0.776-1.196)	0.735	N/A	N/A
PS score in points, 0 or 1 vs 2 or 3	1.142 (0.745-1.753)	0.542	N/A	N/A
Differentiation, moderate or well vs poor	0.947 (0.622-1.441)	0.800	N/A	N/A
Number of metastases, < 2 vs ≥ 2	1.416 (0.947-2.118)	0.090	N/A	N/A
CEA level, < 5 vs ≥ 5	1.707 (1.144-2.548)	0.009	1.650 (1.102-2.469)	0.015
Smoking history, yes vs no	0.956 (0.794-1.151)	0.634	N/A	N/A
Presence of sarcopenia, yes vs no	9.512 (5.489-16.484)	0.000	9.542 (5.398-16.867)	0.000
BMI in kg/m2: underweight, < 18.5; normal, 18.5-24.9; overweight, 25.0-29.9; obese, > 30.0	0.914 (0.722-1.157)	0.456	N/A	N/A

BMI: Body mass index; CEA: Carcinoembryonic antigen; CI: Confidence interval; N/A: Not applicable; HR: Hazard ratio; PS: Performance status.